Activation of neuroprotective pathways by metabotropic group I glutamate receptors: A potential target for drug discovery?

Annals of the New York Academy of Sciences

Volumn 1053, Issue , 2005, Pages 55-73

  Baskys, Andrius ^a,b,c,d   Fang, Liwei ^a   Bayazitov, Ildar ^a,c  

^a Southern California Institute for Research and Education   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE   (United States)

Author keywords

Cholesterol; DHPG; GABARAP; Neuroprotection; Organotypic; Quetiapine; Rab5b

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 2,5 PYRROLIDINEDIONE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3,5 DIHYDROXYPHENYLGLYCINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 CARBOXY 2 METHYLPHENYLGLYCINE; COMPLEMENTARY DNA; GUANOSINE TRIPHOSPHATASE; METABOTROPIC RECEPTOR 1; METHYL BETA CYCLODEXTRIN; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; NEUROPROTECTIVE AGENT; PHOSPHOLIPASE C; PROTEIN RAB5B; PSYCHOTROPIC AGENT; QUETIAPINE; RAB PROTEIN; UNCLASSIFIED DRUG;

CELL ADHESION; CELL DAMAGE; CELL DEATH; CONFERENCE PAPER; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESEARCH; DRUG TARGETING; ENDOCYTOSIS; ENZYME ACTIVATION; GABARAP GENE; GENE; HUMAN; HUMAN CELL; INFLAMMATION; NERVE CELL; NEUROPROTECTION; TRANSCRIPTION REGULATION;

EID: 29744470779     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1344.006     Document Type: Conference Paper

References (89)

1. WOLF, P.A. 1997. Epidemiology and risk factor management. In Primer on Cerebrovascular Diseases. Academic Press. San Diego.
2. GLADSTONE, D.J., S.E. BLACK & A.M. HAKIM. 2002. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33: 2123-2136.
3. CHOI, D.W. & S.M. ROTHMAN. 1990. The role of glutamate neurotoxicity in hypoxic ischemic neuronal death. Annu. Rev. Neurosci. 13: 171-182.
4. COYLE, J.T. & P. PUTTFARKEN. 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262: 689-695.
5. MUIR, K.W & K.R. LEES. 1995. Clinical experience with excitatory amino acid antagonist drugs. Stroke 26: 503-513.
6. OLNEY, J.W. 1969. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 164: 719-721.
7. WATKINS, J.C. & R.H. EVANS. 1981. Excitatory amino acid transmitters. Annu. Rev. Pharmacol. Toxicol. 21: 165-204.
8. DINGLEDINE, R. et al. 1999. The glutamate receptor ion channels. Pharmacol. Rev. 51: 7-61.
9. BUDD, S.L. 1998. Mechanisms of neuronal damage in brain hypoxia/ischemia: focus on the role of mitochondrial calcium accumulation. Pharmacol. Ther. 80: 203-229.
10. MARTIN, L.J. et al. 1998. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res. Bull. 46: 281-309.
11. PORTERA-CAILLIAU, C., D.L. PRICE & L.J. MARTIN. 1997. Excitotoxic neuronal death in the immature brain is an apoptosis-necrosis morphological continuum. J. Comp. Neurol. 378: 70-87.
12. SLOVITER, R.S. 2002. Apoptosis: a guide for the perplexed. Trends Pharmacol. Sci. 23: 19-24.
13. NITATORI, T. et al. 1995. Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. J. Neurosci. 15: 1001-1011.
14. ENDRES, M. et al. 1998. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of caspase family. J. Cereb. Blood Flow Metab. 18: 238-247.
15. SLADECZEK, F. et al. 1985. Glutamate stimulates inositol phosphate formation in striatal neurones. Nature 317: 717-719.
16. NICOLETTI, F. et al. 1986. Coupling of inositol phospholipid metabolism with excitatory amino acid recognition sites in rat hippocampus. J. Neurochem. 46: 40-46.
17. NICOLETTI, F. et al. 1986. The activation of inositol phospholipid metabolism as a signal-transducing system for excitatory amino acids in primary cultures of cerebellar granule cells. J. Neurosci. 6: 1905-1911.
18. BASKYS, A. 1994. Metabotropic Glutamate Receptors. R. G. Landes Press. Austin, TX.
19. BRAUNER-OSBORNE, H. et al. 2000. Ligands for glutamate receptors: design and therapeutic prospects. Med. Chem. 43: 2609-2645.
20. BALAZS, R. et al. 1989. N-Methyl-D-aspartate promotes the survival of cerebellar granule cells: pharmacological characterization. Neurosci. Lett. 101: 241-246.
21. MARINI, A.M. & S.M. PAUL. 1992. N-Methyl-D-aspartate receptor-mediated neuroprotection in cerebellar granule cells requires new RNA and protein synthesis. Proc. Natl. Acad. Sci. USA 89: 6555-6559.
22. PANTAZIS, N.J. et al. 1995. NMDA prevents alcohol-induced neuronal cell death of cerebellar granule cells in culture. Alcohol Clin. Exp. Res. 19: 846-853.
23. KOH, J.Y., E. PALMER & C.W. COTMAN. 1991. Activation of metabotropic glutamate receptors attenuates N-methyl-D-aspartate neurotoxicity in cortical cultures. Proc. Natl. Acad. Sci. USA 88: 9431-9435.
24. CHIAMULERA, C. et al. 1992. Activation of metabotropic receptors has a neuroprotective effect in a rodent model of focal ischemia. Eur. J. Pharmacol. 216: 335-336.
25. OPITZ, T. & G. REYMAN. 1993. (1S,3R)-ACPD protects synaptic transmission from hypoxia in hippocampal slices. Neuropharmacology 32: 103-113.
26. SAGARA, Y. & D. SCHUBERT. 1998. The activation of metabotropic glutamate receptors protects nerve cells from oxidative stress. J. Neurosci. 18: 6662-6671.
27. SCHRODER, U.H. et al. 1999. Protective effect of group I metabotropic glutamate receptor activation against hypoxic/hypoglycemic injury in rat hippocampal slices: timing and involvement of protein kinase C. Neuropharmacology 38: 209-216.
28. KALDA, A. et al. 2000. Neuroprotective action of group I metabotropic glutamate receptor agonists against oxygen-glucose deprivation-induced neuronal death. Brain Res. 853: 370-373.
29. REBECCHI, M.J. & S.N. PENTYALA. 2000. Structure, function, and control of phosphoinositide-specific phospholipase C. Physiol. Rev. 80: 1291-1335.
30. MACDONALD, J.F., J.M. WOJTOWICZ & A. BASKYS. 1996. Glutamate receptors. In Brain Mechanisms and Psychotropic Drugs. CRC Press. Boca Raton, FL.
31. PELLEGRINI-GIAMPIETRO, D.E., S.A. TORREGROSSA & F. MORONI. 1996. Pharmacological characterization of metabotropic glutamate receptors coupled to phospholipase D in the rat hippocampus. Br. J. Pharmacol. 118: 1035-1043.
32. PISANI, A. et al. 2001. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106: 579-587.
33. SKEBERDIS, V.A. et al. 2001. mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C. Neuropharmacology 40: 856-865.
34. BANDROWSKI, A.E. et al. 2001. Metabotropic glutamate receptors modify ionotropic glutamate responses in neocortical pyramidal cells and interneurons. Exp. Brain. Res. 136: 25-40.
35. AWAD, H. et al. 2000. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 20: 7871-7879.
36. O'LEARY, D.M. et al. 2000. Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br. J. Pharmacol. 131: 1429-1437.
37. RAO, A.M., J.F. HATCHER & R.J. DEMPSEY. 2000. Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil. Neurosci. Lett. 293: 1-4.
38. CHUANG, S.C. et al. 2001. Group I metabotropic glutamate receptors elicit epileptiform discharges in the hippocampus through PLCβ1 signaling. J. Neurosci. 21: 6387-6394.
39. BRUNO, V. et al. 1995. Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells. Neuropharmacology 34: 1089-1098.
40. MAIESE, K. et al. 1995. Activation of the metabotropic glutamate receptor is neuroprotective during nitric oxide toxicity in primary hippocampal neurons of rats. Neurosci. Lett. 194: 173-176.
41. VINCENT, A.M. et al. 1997. Metabotropic glutamate receptors prevent nitric oxide-induced programmed cell death. J. Neurosci. Res. 50: 549-564.
42. VINCENT, A.M., M. TENBROEKE & K. MAIESE. 1999. Metabotropic glutamate receptors prevent programmed cell death through the modulation of neuronal endonuclease activity and intracellular pH. Exp. Neurol. 155: 79-94.
43. VINCENT, A.M. & K. MAIESE. 2000. The metabotropic glutamate system promotes neuronal survival through distinct pathways of programmed cell death. Exp. Neurol. 166: 65-82.
44. ALLEN, J.W., S.M. KNOBLACH & A.I. FADEN. 2000. Activation of group I metabotropic glutamate receptors reduces neuronal apoptosis, but increases necrotic cell death in vitro. Cell Death Differ. 7: 470-476.
45. COLWELL, C.S., K.L. ALTEMUS & M.S. LEVINE. 1996. Metabotropic glutamate receptor activation selectively limits excitotoxic damage in the intact neostriatum. Brain Res. 726: 223-226.
46. ADAMCHIK, Y. & A. BASKYS. 2000. Glutamate-mediated neuroprotection against N-methyl-D-aspartate toxicity: a role for metabotropic glutamate receptors. Neuroscience 99: 731-736.
47. BRUNO, V. et al. 2001. An activity-dependent switch from facilitation to inhibition in the control of excitotoxicity by group I metabotropic glutamate receptors. Eur. J. Neurosci. 13: 1469-1478.
48. CALABRESI, P. et al. 2000. Is pharmacological neuroprotection dependent on reduced glutamate release? Stroke 31: 766-772.
49. ROSSI, D.J., T. OSHIMA & D. ATTWELL. 2000. Glutamate release in severe brain ischaemia is mainly by reversed uptake. Nature 403: 316-321.
50. BEHRENS, M.M. et al. 1999. Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity. Neuropharmacology 38: 1621-1630.
51. LAFON-CAZAL, M. et al. 1999. mGluR7-like receptor and GABA(B) receptor activation enhance neurotoxic effects of N-methyl-D-aspartate in cultured mouse striatal GABAergic neurones. Neuropharmacology 38: 1631-1640.
52. LAFON-CAZAL, M. et al. 1999. mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons. Eur. J. Neurosci. 11: 663-672.
53. BLAABJERG, M., L. FANG, J. ZIMMER & A. BASKYS. 2003. Neuroprotection against NMDA excitotoxicity by group I metabotropic glutamate receptors is associated with reduction of NMDA stimulated currents. Exp. Neurol. 183: 573-580.
54. (a) IRELAND, D.R. & W.C. ABRAHAM. 2002. Group I mGluRs increase excitability of hippocampal CA1 pyramidal neurons by a PLC-independent mechanism. J. Neurophysiol. 88: 107-116;
55. (b) BAYAZITOV, I.T., L. FANG & A. BASKYS. 2004. Neuroprotection by group I metabotropic glutamate receptor agonist DHPG requires activation of phospholipase C. Program no. 952.7 [online]. Abstract Viewer/Itinerary Planner. Society for Neuroscience. Washington, D.C.
56. PIZZI, M. 1996. Activation of multiple metabotropic glutamate receptor subtypes prevents NMDA-induced excitotoxicity in rat hippocampal slices. Eur. J. Neurosci. 8: 1516-1521.
57. YU, S.P. et al. 1997. Membrane-delimited modulation of NMDA currents by metabotropic glutamate receptor subtypes 1/5 in cultured mouse cortical neurons. J. Physiol. 499: 721-732.
58. SNYDER, E.M. et al. 2001. Internalization of ionotropic glutamate receptors in response to mGluR activation. Nat. Neurosci. 4: 1079-1085.
59. BLAABJERG, M. et al. 2003. Changes in hippocampal gene expression after neuroprotective activation of group I metabotropic glutamate receptors. Mol. Brain Res. 117: 196-205.
60. ZERIAL, M. & H. MCBRIDE. 2001. Rab proteins as membrane organizers. Nat. Rev. Mol. Cell. Biol. 2: 107-117.
61. BASKYS, M. & M. BLAABJERG. 2005. Understanding regulation of nerve cell death by mGluRs as a method for development of successful neuroprotective strategies. J. Neurol. Sci. In press.
62. ROCHE, K.W. et al. 2001. Molecular determinants of NMDA receptor internalization. Nat. Neurosci. 4: 794-802.
63. MAN, H.Y. et al. 2000. Regulation of AMPA receptor-mediated synaptic transmission by clathrin-dependent receptor internalization, Neuron 25: 649-662.
64. ARNETT, A.L.H. et al. 2004. Antisense oligonucleotide against GTPase Rab5b inhibits metabotropic agonist DHPG-induced neuroprotection. Brain Res. 1028: 59-65.
65. DIAS, N. & C.A. STEIN. 2002. Potential roles of antisense oligonucleotides in cancer therapy: the example of Bcl-2 antisense oligonucleotides. Eur. J. Pharm. Biopharm. 54: 263-269.
66. BUCCI, C. et al. 1995. Cooperative regulation of endocytosis by three Rab5 isoforms, FEBS Lett. 366: 65-71.
67. CHAVRIER, P., K. SIMONS & M. ZERIAL. 1992. The complexity of the Rab and Rho GTP-binding protein subfamilies revealed by a PCR cloning approach. Gene 112: 261-264.
68. WILSON, D.B. & M.P. WILSON. 1992. Identification and subcellular localization of human Rab5b, a new member of the Ras-related superfamily of GTPases. J. Clin. Invest. 89: 996-1005.
69. 125I] iodixanol in rat liver parenchymal, endothelial, and Kupffer cells. Cell Tissue Res. 304: 221-230.
70. BAVRO, V.N. et al. 2002. Crystal structure of the GABA(A)-receptor- associated protein, GABARAP. EMBO Rep. 3: 183-189.
71. COYLE, J.E. et al. 2002. Structure of GABARAP in two conformations: implications for GABA(A) receptor localization and tubulin binding. Neuron 33: 63-74.
72. A receptor clustering and modulates the channel kinetics. Proc. Natl. Acad. Sci. USA 97: 11557-11562.
73. KENNEDY, M.B. 2000. Sticking together. Proc. Natl. Acad. Sci. USA 97: 11135-11136.
74. A receptor agonist THIP is neuroprotective in organotypic hippocampal slice cultures. Brain Res. 973: 303-306.
75. A receptors. J. Neurochemistry 80: 815-823.
76. GIMPL, G., K. BURGER & F. FAHRENHOLZ. 1997. Cholesterol as modulator of receptor function. Biochemistry 36: 10959-10974.
77. SOOKSAWATE, T. & M.A. SIMMONDS. 2001. Influence of membrane cholesterol on modulation of the GABA(A) receptor by neuroactive steroids and other potentiators. Br. J. Pharmacol. 134: 1303-1311.
78. THOMPSON, P.M. et al. 2001. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl. Acad. Sci. USA 98: 11650-11655.
79. SEEMAN, M.V. 1997. Psychopathology in women and men: focus on female hormones. Am. J. Psychiatry 154: 1641-1647.
80. COPOLOV, D. et al. 2000. Neurobiological findings in early phase schizophrenia. Brain Res. Brain Res. Rev. 31: 157-165.
81. LIEBERMAN, J.A. et al. 2002. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 50: 884-897.
82. (Erratum: Biol. Psychiatry 51: 346.)
83. DEAKIN, J.F. & M.D. SIMPSON. 1997. A two-process theory of schizophrenia: evidence from studies in post-mortem brain. J. Psychiatry Res. 31: 277-295.
84. GEYER, M.A. 1998. Behavioral studies of hallucinogenic drugs in animals: implications for schizophrenia research. Pharmacopsychiatry 31(suppl. 2): 73-79.
85. NINAN, I., K.E. JARDEMARK & R.Y. WANG. 2003. Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex. Neuropharmacology 44: 462-472.
86. TARAZI, F.I. et al. 2003. Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 306: 1145-1151.
87. KINNEY, G G. et al. 2004. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. [Epub ahead of print].
88. LI, X.M. et al. 1999. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J. Neurosci. Res. 56: 72-75.
89. XU, H. et al. 2002. Quetiapine attenuates the immobilization stress-induced decrease of brain-derived neurotrophic factor expression in rat hippocampus. Neurosci. Lett. 321: 65-68.